SPOTLIGHT -
OTE Readership Survey 2006
Exonate shares results from Phase Ib/IIa trial of EXN407 eye drops for DR and DME
In addition to the primary safety and tolerability endpoints, the study also saw signals of biological response from EXN407
Novel Therapies in Neovascular AMD and DME: Achieving Superior Anatomic Outcomes with Fewer Injections
Outlook Therapeutics receives positive CHMP opinion for bevacizumab for wet age-related macular degeneration
The European Commission is expected to make a decision about the application before the end of June
Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO
How amyloid-beta peptide and tau protein demonstrate degeneration
Proteins common to Alzheimer disease play a significant role in glaucoma
Focusing on functional vision with monofocal lenses
Quantitative and qualitative improvement in IOL design